Report forecast the global systemic psoriasis therapeutics
market to grow at a CAGR of 9.41% during the period 2016-2020.
Psoriasis is a commonly diagnosed immune-mediated disease of
the skin. In psoriasis, the skin grows fast and causes a build-up of red, thick
white, or silvery patches. It modifies the normal cell cycle of the skin such
that new cells move to the surface of the skin quickly to form patches called
plaques. These plaques are commonly found on the knees, elbows, scalp, hand and
feet. The condition mostly occurs among adults (18 years-35 years), but can
also be seen in adolescents (12 years-18 years) and children (under 10 years).
Psoriasis is more prevalent among Caucasians compared to
African-Americans. According to a World Health Organization (WHO) document of
2015, the global prevalence of psoriasis is approximately 2%-3%. However, it is
approximately 4.6% in developed countries. In addition, the risk of an
individual getting diagnosed with psoriasis is 41% if both parents have
psoriasis, 14% in case one parent is affected, and 6% if a sibling has
psoriasis.
The report covers the present scenario and the growth
prospects of the global systemic psoriasis therapeutics market for 2016-2020.
To calculate the market size, Technavio considers the revenue generated from
the from the sales of branded, generic, and off-label drugs used to treat
psoriasis. It also considers the revenues to be generated from the sales of
drugs that are expected to be launched into the market along with the decline
in revenues from the patent expiries of marketed drugs during the forecast
period.
The market is divided into the following segments based
on geography:
- Americas
- APAC
- EMEA
According to the report, factors such as the dominance of
market by biologics will drive this market’s growth prospects for the near
future. Biologics account for over 18% of the global pharmaceutical sales,
outpacing the sales of branded pharmaceuticals. These drugs will continue to
outperform other pharmaceuticals in terms of product sales as there is an
increasing need for innovative products as effective treatment options for a
range of indications.
Further, the report states that one challenge impeding this
market’s growth is the physician's reluctance to prescribe biosimilars.
Physicians are reluctant to prescribe biosimilars to patients as biologics
cannot be substituted with these drugs. Biologics are developed using a living
system or a genetically modified organism. A slight variation in the
manufacturing process, in terms of conditions and formulation, of biosimilar
products can affect the safety and efficacy of the final product. These drugs can
also not be used during post-marketing surveillance, as the substitution of
drugs is prohibited during this period.
Global Systemic Psoriasis Therapeutics Market 2016-2020,
has been prepared based on an in-depth market analysis with inputs from
industry experts. The report covers the market landscape and its growth
prospects over the coming years. The report also includes a discussion of the
key vendors operating in this market.
key players in the global systemic psoriasis therapeutics
market: AbbVie, Johnson & Johnson, Celgene, Amgen, and Pfizer.
Other Prominent Vendors in the market are: AbGenomics,
Almirall, Anacor Pharmaceuticals, ApoPharma, Astellas Pharma, AstraZeneca,
Aurinia Pharmaceuticals, Biocon, Biogen Idec, Biotest, Boehringer Ingelheim, Bristol-Myers
Squibb, Can-Fite BioPharma, Cellceutix Corporation, Coherus Biosciences,
Creabilis, Crescendo Biologics, Delenex Therapeutics, Dermira, Eli Lilly, F.
Hoffmann-La Roche, Forward Pharma, G & W Laboratories, GlaxoSmithKline,
Idera Pharmaceuticals, Incyte Corporation, Kadmon, kinetabio, KPI Therapeutics,
Kyowa Hakko Kirin, LEO Pharma, Maruho, Merck, Mitsubishi Tanabe Pharma,
Moleculin, MorphoSys, Novartis, Pfizer, Prism Pharma, Promius Pharma, Prothena
Biosciences, Provectus Biopharmaceuticals, Sandoz, Sun Pharmaceuticals, Takeda
Pharmaceuticals, Taro Pharmaceuticals, TFS Corp, Therapeutics, UCB, Valeant
Pharmaceuticals, VBL Therapeutics, XenoPort, and Ziarco Pharma.
Market driver
- Dominance of market by biologics
- For a full, detailed list, view our report
Market challenge
- Physician's reluctance to prescribe biosimilars
- For a full, detailed list, view our report
Market trend
- Advent of biologics with novel MOA and cell-based strategies
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Spanning over 88 pages and 70 Exhibit “Global
Systemic Psoriasis Therapeutics Market 2016 - 2020” report covers Executive
summary, Scope of the report, Market research methodology, Introduction, Market
landscape, Psoriasis: Condition overview, Pipeline analysis, Market
segmentation by type of molecule, Market segmentation by mechanism of action,
Market segmentation by severity of disease, Market segmentation by ROA,
Geographical segmentation, Market drivers, Impact of drivers, Market
challenges, Impact of drivers and challenges, Market trends, Vendor landscape,
Appendix.
For
more information Visit at: http://mrr.cm/Ja3
Related Reports;
Global Vascular Closure Devices Market 2016-2020 - Visit at
- http://mrr.cm/JaU
Global Nuclear Medicine Market 2016-2020 - Visit at - http://mrr.cm/Jaw
Global Cardiac Resynchronization Therapy Pacemaker Market
2016-2020 - Visit at - http://mrr.cm/Jai
No comments:
Post a Comment
Note: only a member of this blog may post a comment.